We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 4.08% at $19.50. The stock's change was less than the S&P 500's daily gain of 0.08%. Elsewhere, the Dow lost 0.18%, while the tech-heavy Nasdaq added 0.1%.
Shares of the company have depreciated by 8.26% over the course of the past month, underperforming the Medical sector's loss of 6.98%, and the S&P 500's loss of 1.74%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. The company is predicted to post an EPS of $0.02, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $621.4 million, up 6.04% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.48 per share and revenue of $2.86 billion. These totals would mark changes of -9.43% and +21.88%, respectively, from last year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.44% lower within the past month. At present, Hims & Hers Health, Inc. boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Hims & Hers Health, Inc. is at present trading with a Forward P/E ratio of 42.61. For comparison, its industry has an average Forward P/E of 19.91, which means Hims & Hers Health, Inc. is trading at a premium to the group.
Also, we should mention that HIMS has a PEG ratio of 2.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Info Systems industry stood at 1.13 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 85, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 4.08% at $19.50. The stock's change was less than the S&P 500's daily gain of 0.08%. Elsewhere, the Dow lost 0.18%, while the tech-heavy Nasdaq added 0.1%.
Shares of the company have depreciated by 8.26% over the course of the past month, underperforming the Medical sector's loss of 6.98%, and the S&P 500's loss of 1.74%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. The company is predicted to post an EPS of $0.02, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $621.4 million, up 6.04% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.48 per share and revenue of $2.86 billion. These totals would mark changes of -9.43% and +21.88%, respectively, from last year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.44% lower within the past month. At present, Hims & Hers Health, Inc. boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Hims & Hers Health, Inc. is at present trading with a Forward P/E ratio of 42.61. For comparison, its industry has an average Forward P/E of 19.91, which means Hims & Hers Health, Inc. is trading at a premium to the group.
Also, we should mention that HIMS has a PEG ratio of 2.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Info Systems industry stood at 1.13 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 85, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.